Addex Therapeutics Ltd · SIX:ADXN
Addex Therapeutics — Corporate Update (January 2008)
19 slides from Addex Therapeutics's corporate update, January 2008
Slide 1: Addex and Merck & Co., Inc. the mGluR5 PAM deal
Addex and Merck & Co., Inc. the mGluR5 PAM deal test
Slide 2: Agreement
Agreement • Merck received an exclusive license to develop Addex’ ADX63365 and associated backup compounds • ADX63365 is a metabotropic glutamate receptor 5 (mGluR5) positive allosteric modulator (PAM) • ADX63365 is a drug candidate for schizophrenia and other conditions • Merck is responsible for c
Slide 3: Financial Terms
Financial Terms • Addex receives $22 million upfront • Addex is eligible to receive $455 million in research, development, regulatory and sales milestones for the first product in two indications • Addex is eligible for an additional $225 million in development, regulatory and sales milestones for a
Slide 4: Financial Guidance
Financial Guidance • Full year unaudited cash burn for 2007 is CHF37.7m – Operating cash burn is CHF35.0m – Capex cash burn is CHF2.7m • Full year cash burn guidance for 2008 is CHF25 to 30 million – Operating cash burn of CHF20 to 23m – Capex cash burn of CHF5 to 7m test
Slide 5: Schizophrenia
E Pharmaceuticals Schizophrenia
Slide 6: Schizophrenia
Schizophrenia Schizophrenia is a chronic, severe, and disabling brain disease Epidemiology • Affects ~ about 1.1% of the U.S. population over 18, according to NIMH • Appears in the late teens to early thirties (earlier in males) • Estimates suggest that no more than one in five individuals recovers
Slide 7: mGluR5 PAM in Schizophrenia
mGluR5 PAM in Schizophrenia test
Slide 8: mGluR5 in Schizophrenia
mGluR5 in Schizophrenia • In preclinical testing, mGluR5 activation has shown anti-psychotic effects similar to marketed drugs • Anti-psychotic effect allows pursuit of first-line monotherapy label – Novel mechanism suggests the possibility of avoiding side effects associated with poor compliance wi
Slide 9: mGluR5 PAM & mGluR2 PAM
mGluR5 PAM & mGluR2 PAM different approaches to treating Schizophrenia test
Slide 10: mGluR2 & mGluR5 PAM
mGluR2 & mGluR5 PAM • mGluR2/3 activation is clinically validated in schizophrenia (and anxiety) – mGluR2/3 agonist efficacious on positive and negative symptoms of schizophrenia – mGluR2/3 agonist efficacy similar to olanzapine BUT: • no weight gain • no EPS • no hyperprolactinemia • mGluR5 rationa
Slide 11: Allosteric Modulators
Allosteric Modulators Addex’ goal is to become a world class pharmaceutical company test
Slide 12: Allosteric Modulation
Allosteric Modulation ~a non-competitive approach~ Negative Allosteric Positive Modulator Allosteric Modulator Endogenous ligand Orthosteric agonists and antagonists compete for the same « active site » targeted by the natural outside of cell activators (i.e. endogenous ligands). cell Allosteric mod
Slide 13: Orthosteric ≠ Allosteric
Orthosteric ≠ Allosteric Orthosterics are steady state Allostery preserves natural rhythm PAM + natural ligand Biological response Biological response Agonist Natural ligand Natural ligand NAM + natural ligand Antagonist Time Time • PAMs & NAMs do not activate/deactivate receptors – the natural liga
Slide 14: Addex can target all GPCR Families
Addex can target all GPCR Families Family 1 Family 2 Calcitonin Muscarinic receptors PTH Odorants VIP Catecholamines PACAP Adenosine GnRH Opioid receptors CRF Anandamide GLP-1 Glucagon Peptides GIP Cytokines II8 Family 3 Formyl Met-Leu-Phe fMLP-peptide PAF-acether Thrombin mGluR1-8 Ca++ GABAb Pherom
Slide 15: Addex Pipeline
> Pharmaceuticals Addex Pipeline a
Slide 16: Allosteric Modulator Pipeline
Allosteric Modulator Pipeline Discovery Preclinical Phase I Phase IIa Milestones Partner ADX10059 (metabotropic glutamate receptor 5 NAM) ADX10059 (metabotropic glutamate receptor 5 NAM) Ph IIa endpoint met Gastroesophageal Reflux Disease (GERD) Gastroesophageal Reflux Disease (GERD) Ph IIb start: m
Slide 17: Deals Bring More Validation for Addex
Deals Bring More Validation for Addex test
Slide 18: The Four Major Validations for Addex' Allosteric Modulator Platform
The Four Major Validations for Addex’ Allosteric Modulator Platform 1) Finding drug-like mGluR5 PAMs has been challenging for pharma. This deal provides Merck exclusive rights to Addex’ ADX63365, a selective mGluR5 PAM, as well as multiple backup compounds 2) Finding drug-like mGluR4 PAMs has been c
Slide 19: Allosteric modulators for human health Q&A
allosteric modulators for human health Q&A www.addexpharma.com test